Breaking News

AbbVie To Establish Manufacturing Ops in Singapore

To invest $320 million in capacity for oncology and immunology pipeline

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie is investing $320 million to establish manufacturing operations in Singapore for small molecule and biologics active drug substance. Once completed, the facility will provide manufacturing capacity for compounds in AbbVie’s oncology and immunology pipeline to serve global markets. The investment is expected to result in additional headcount of more than 250 new employees. AbbVie anticipates the facility will be fully operational by 2019.   AbbVie’s operations in Asia currently inclu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters